Dan Burton: Yes. I appreciate that, Richard. I think we have striven to incorporate lots of feedback from our client base and from our prospective client base about what they’re facing and be really realistic about the headwinds that they’re facing and that, therefore, might translate to headwinds in parts of our portfolio that we would face in our discussions with them. And I think we have a much deeper understanding of that at this time this year than certainly we did at this time last year. I think our clients didn’t have a full understanding of the headwinds this time last year. So that is certainly much more deeply embedded in the forecast. I’d say another element that we’ve talked about in the prepared remarks and in the Q&A is the foundation of growth for Health Catalyst moving forward from a go-to-market perspective is our existing clients and their expansion.
We’ve reengaged at a really deep level with those existing clients. I referenced in our prepared remarks that now I’ve had over 80 face-to-face C-suite executive discussions over the last six months or so. And that is consistent with what our team is doing now. We’re reengaging with more face-to-face discussions, more of a deep investment in those existing client relationships. And I think that gives an increased confidence level, especially as it relates to that foundational growth element, of the kind of opportunities for expansion that exists for us in the pipeline with our existing clients. And then I think we’re trying to take the same approach with prospective clients. The data informed. We’re taking more time to spend face-to-face time with those prospective clients and let that inform our perspective moving forward.
Richard Close: Appreciated. Thank you.
Dan Burton: Thanks, Richard.
Operator: Thank you. Our next question will come from Sean Dodge with RBC Capital Markets. Your line is open.
Thomas Kelliher: Hey good afternoon. This is Thomas Kelliher on for Sean. Thanks for taking my question. So, I wanted to go back to the Carle Health expansion. You mentioned the revenue opportunity before is like up to $16 million per year. How much of that is included in the 2023 guidance? And I wanted to confirm, is that $16 million pretty much locked in? Or is there any portion of that going to be performance-based? Thanks.
Dan Burton: Yes. Thank you, Thomas. So all of that $16 million is locked in, and it is all included in a five-year contract structure with Carle Health. And so that is embedded in the 2023 revenue guidance given that we signed that deal late last year. So that is included in 2023.
Bryan Hunt: And just to add to that, there are no other kind of performance-based components €“ at-risk components in terms of that contract structure because Carle wanted to have the visibility around what they’d be spending as well, which is kind of part of the value proposition of locking in that spend, especially on the services side, where they’re having retention issues as well as feeling the significant impacts from inflation on that type.
Thomas Kelliher: Burton, great, thank you.
Dan Burton: Thanks, Thomas.
Operator: Operator Thank you. Our next question will come from David Larsen with BTIG. Your line is open.
